Silver Range Resources Ltd (TSX-V:SNG, OTC:SLRRF) announced that it has struck a definitive agreement to option its Bellehelen project in Nevada to Excalibur Metals Corp.
Excalibur, a private British Columbia company, will receive an option to purchase a 100% interest in Bellehelen for a cash payment of $300,000 and 200,000 Excalibur shares over four years; a 2% net smelter return; and a US$2 per ounce gold-equivalent payment on any future defined resource payable on the exercise of the option.
American Resources Corporation (NASDAQ:AREC) said it has executed its second rare earth oxide offtake agreement with Advanced Magnet Lab Inc (AML) to provide AML high-purity raw rare earth elemental feedstock for its advanced, domestic magnet production.
The company noted that concurrent with the offtake agreement, it has completed an initial strategic investment into AML to further advance the technology and commercialization.
Ncondezi Energy Ltd (AIM:NCCL, OTC:NCDZF) has signed a master services agreement with Synergy Consulting to provide financial and transaction advisory services for its 300MW solar project in Mozambique.
According to a statement from Ncondezi, which is developing the solar photovoltaic (PV) and battery energy storage system (BESS) project in Tete, Mozambique, the agreement covers potential advisory services to accelerate the project up to financial close.
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said its dry eye disease treatment has received clearance for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to initiate a phase 2 study.
First-in-human clinical studies of OK-101 are expected to open for enrolment in the first quarter of 2023, the biopharmaceutical company said.
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) has expressed optimism about 2023, during which it aims to progress its lupus treatment Lupuzor to its next clinical trial.
In an update to the market, the specialist drug discovery and development company said it continues to work proactively, together with its partner Avion Pharmaceuticals and external advisors, on the preparations around the proposed updated P140 (Lupuzor) clinical programme for 2023.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) said it received a contract for an additional programme for its FOVIO Driver and Occupant Monitoring System from an existing European Tier-1 vehicle manufacturing customer.
The programme, which carries an initial lifetime value of US$32mln (A$45mln), is scheduled to start production in 2024 and will see Seeing Machines' software embedded across a broad range of models, including entry level vehicles.
archTIS Ltd welcomes its rebate payment of A$1.785 million from the Australian Taxation Office (ATO) relating to the company’s refundable tax offset claim for the fiscal year ending June 30, 2022.
“The R&D tax rebate is an important component of our overall corporate finance strategy,” archTIS global COO Kurt Mueffelmann said.
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that it has submitted the Type C meeting request package to the US Food & Drug Administration (FDA) to obtain agreement on the revised protocol endpoints for the company’s Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Following the submission of the Type C meeting request package, Revive said it expects to hear from the FDA on a firm date for the meeting.
Think Research Corporation (TSX-V:THNK, OTCQB:THKKF) said it has granted 246,485 restricted share units (RSUs) to a key employee of the company under the company's omnibus equity incentive plan (OEIP). A total of 146,485 of the RSUs will vest one year from today's date, and 100,000 will vest two years from today's date. Each RSU represents the right to receive, once vested, one common share. Further, the company also announced that it has granted 1.06 million stock options to key employees of the company pursuant to the company's OEIP. The options will vest one-third annually over three years from December 21, 2022.
Maverix Metals Inc (TSX:MMX) has announced the details of a special meeting of shareholders in connection with the previously announced statutory plan of arrangement under which, among other things, Triple Flag Precious Metals Corp will acquire all of the issued and outstanding common shares of Maverix The special meeting will be held on Thursday, January 12, 2023, at 10.00am Pacific time in a virtual format. Shareholders of record as of the close of business on December 2, 2022, are entitled to receive notice of, to participate in, and to vote their shares of Maverix at the special meeting. Implementation of the arrangement is subject to the approval of: (i) at least two-thirds (66 2/3%) of the votes cast by shareholders virtually present or represented by proxy at the special meeting, voting as a single class; and (ii) because the Arrangement is subject to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions, a simple majority (more than 50%) of the votes cast by shareholders virtually present or represented by proxy at the special meeting, excluding the votes of shareholders whose votes are required to be excluded pursuant to MI 61-101. In addition to the receipt of the requisite approval of Maverix shareholders, completion of the arrangement is subject to final approval by the Court and the satisfaction or waiver of the other customary conditions to completion.
OTC Markets Group Inc. (OTCQX:OTCM), the operator of regulated markets for 12,000 US and international securities, has announced that Marimaca Copper Corp, a Canadian copper company, has qualified to trade on the OTCQX Best Market and has today upgraded from the Pink market under the symbol MARIF. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their US investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the US. To qualify for OTCQX, companies must meet high financial standards, follow best-practice corporate governance and demonstrate compliance with applicable securities laws. “We are very pleased to complete our upgrade to OTCQX. Marimaca is rapidly progressing toward development and we look forward to engaging with a broader range of investors in the US market at this exciting time for the company," said Hayden Locke, Marimaca Copper president and CEO.
BANXA Holdings Inc (TSX-V:BNXA, OTCQX:BNXAF) issued an update on the status of its trade cessation status, announcing that continued progress has been made with its auditor, RSM Canada, on completing its audited financial statements for the fiscal year ended June 30. The company expects the audit to be completed in the new year. Additionally, Banxa said it successfully signed and executed more than 30 paid integrations and token listing fees in October through December, good for an additional AUD$500,000 in gross profit margin contribution.